Aug 7, 2026 07:32AM
Aug 7, 2026 07:02AM
Aug 6, 2026 04:30PM
Jul 21, 2026 09:23AM
Jun 16, 2026 06:43AM
Jun 15, 2026 06:01AM
Jun 3, 2026 09:02AM Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential
May 13, 2026 05:40AM
May 12, 2026 05:47AM
May 11, 2026 04:20PM
May 11, 2026 04:03PM
Apr 29, 2026 06:59AM
Apr 13, 2026 08:39AM
Apr 7, 2026 11:08AM Leerink Partners on Halozyme Therapeutics (HALO): VRTX partnership 'validation of Hypercon'
Apr 7, 2026 08:05AM
Feb 19, 2026 10:25AM
Feb 18, 2026 08:14AM
Feb 17, 2026 04:06PM
Feb 3, 2026 09:29AM
Jan 29, 2026 06:49AM
Jan 29, 2026 04:44AM Goldman Sachs Reiterates Sell Rating on Halozyme Therapeutics (HALO)
Jan 28, 2026 06:41AM
Jan 8, 2026 09:30AM
Dec 5, 2025 05:18AM
Dec 4, 2025 01:28PM
Dec 4, 2025 06:51AM
Nov 28, 2025 06:34AM
Nov 17, 2025 11:21AM Halozyme Therapeutics (HALO) PT Raised to $56 at Goldman Sachs
Nov 7, 2025 08:31AM
Nov 4, 2025 05:03AM
Nov 3, 2025 04:02PM
Oct 21, 2025 06:46AM
Oct 14, 2025 01:26PM
Oct 2, 2025 06:42AM
Oct 2, 2025 04:28AM Halozyme Therapeutics (HALO) PT Raised to $70 at Leerink Partners
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Oct 1, 2025 04:21AM
Sep 24, 2025 08:20AM
Sep 22, 2025 06:42AM
Aug 12, 2025 04:59AM
Aug 6, 2025 04:08AM Halozyme Therapeutics (HALO) PT Raised to $91 at Citizens JMP
Aug 6, 2025 03:37AM
Aug 5, 2025 04:05PM
Jul 23, 2025 11:39AM
Jul 10, 2025 06:28AM
Jun 30, 2025 04:07PM
Jun 20, 2025 01:15PM
Jun 10, 2025 10:00AM TD Cowen on Halozyme Therapeutics (HALO): 'Potential CMS Impact Analysis Reaffirms Our Buy Rating'
May 29, 2025 06:54AM

443,890 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All